Medicenna Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
MDNA
- Investments
-
1
- Share Price
-
$0.12
- (As of Friday Closing)
Medicenna Therapeutics General Information
Description
Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13 Superkines and empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its platforms are Superkine, BISCUIT, TEMASK, Publications, and Scientific Publications.
Contact Information
Website
www.medicenna.comCorporate Office
- 2 Bloor Street West
- Suite 903
- Toronto, Ontario M4W 3E2
- Canada
Corporate Office
- 2 Bloor Street West
- Suite 903
- Toronto, Ontario M4W 3E2
- Canada
Medicenna Therapeutics Stock Performance
As of 20-Nov-2026, Medicenna Therapeutics’s stock price is $0.12. Its current market cap is $11.3M with 92.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.12 | $0.15 | $0.12 - $1.29 | $11.3M | 92.3M | 74.7K | -$0.16 |
Medicenna Therapeutics Financials Summary
As of 30-Jun-2026, Medicenna Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 21,339 | 30,805 | 32,722 | 79,316 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (13,632) | (13,649) | (9,402) | (19,757) |
| Net Income | (13,430) | (13,318) | (8,471) | (18,873) |
| Total Assets | 5,804 | 6,069 | 19,832 | 14,161 |
| Total Debt | 73 | 85 | 117 | 0 |
Medicenna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medicenna Therapeutics Comparisons
Industry
Financing
Details
Medicenna Therapeutics Competitors (21)
One of Medicenna Therapeutics’s 21 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Cullinan Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Revive Therapeutics | Corporation | Toronto, Canada | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA |
Medicenna Therapeutics Signals
Medicenna Therapeutics Acquisitions (1)
Medicenna Therapeutics’s most recent deal was a Merger/Acquisition with A2 Acquisition. The deal was made on 01-Mar-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| A2 Acquisition | 01-Mar-2017 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Medicenna Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Medicenna Therapeutics FAQs
-
When was Medicenna Therapeutics founded?
Medicenna Therapeutics was founded in 2011.
-
Where is Medicenna Therapeutics headquartered?
Medicenna Therapeutics is headquartered in Toronto, Canada.
-
What is the size of Medicenna Therapeutics?
Medicenna Therapeutics has 20 total employees.
-
What industry is Medicenna Therapeutics in?
Medicenna Therapeutics’s primary industry is Biotechnology.
-
Is Medicenna Therapeutics a private or public company?
Medicenna Therapeutics is a Public company.
-
What is Medicenna Therapeutics’s stock symbol?
The ticker symbol for Medicenna Therapeutics is MDNA.
-
What is the current stock price of Medicenna Therapeutics?
As of 20-Nov-2026 the stock price of Medicenna Therapeutics is $0.12.
-
What is the current market cap of Medicenna Therapeutics?
The current market capitalization of Medicenna Therapeutics is $11.3M.
-
Who are Medicenna Therapeutics’s competitors?
Sarepta Therapeutics, Cullinan Therapeutics, Revive Therapeutics, Genetix Biotherapeutics, and Achaogen are some of the 21 competitors of Medicenna Therapeutics.
-
What is Medicenna Therapeutics’s annual earnings per share (EPS)?
Medicenna Therapeutics’s EPS for 12 months was -$0.16.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process